Oxysterol Platform (Antiviral)

About MAX BioPharma

MAX BioPharma is a preclinical biotech leveraging its proprietary Oxysterol Therapeutics® platform to develop small-molecule lipid drugs. Founded on discoveries from UCLA, the company's most advanced candidate, Oxy210, is an oral, antifibrotic/anti-inflammatory agent being developed for MASH. As a private, preclinical-stage company, MAX BioPharma is targeting large, unmet medical needs across fibrosis, inflammation, and infection, but faces the inherent risks of early-stage drug development and platform validation.

Therapeutic Areas